SUMMARY. The tissue tropism and possible correlation with liver disease of the TT virus (TTV) as well as its prevalence and genotype distribution remain undefined. TTV-DNA was investigated in paired sera and tissue samples from 144 patients, and sera and cerebrospinal fluids (CSF) from additional six subjects. Of the 144 tissue samples, 128 were liver biopsy specimens from subjects with hepatic disease while 16 were surgically obtained nonliver specimens from patients with extrahepatic disease. TTV cloning, sequencing and genotype analyses were performed on isolates from sera, tissue specimens and peripheral blood mononuclear cells of two patients with hepatic and four patients with extrahepatic pathologies, as well as from sera and CSFs of two subjects. TTV was found in 100% of the examined tissues and in 60.1 and 50% of sera from patients with hepatic and extrahepatic pathologies, respectively. Moreover, TTV was detected in four of the six CSFs analysed but only in two correspondent sera. Genotyping revealed the coexistence of multiple TTV genotypes and genetic variants in each infected individual, and the analysis of TTV mRNA showed the presence of transcripts in all the six different tissues studied. These results indicate that the entire adult population in our area is more likely infected by TTV, although several subjects are not viraemic and that TTV infects many different human tissues and is able to invade the central nervous system.
INTRODUCTION
The TT virus (TTV) is a newly discovered nonenveloped DNA virus first recovered from a Japanese patient with posttransfusion hepatitis of unknown aetiology [1, 2] . Preliminary studies found TTV-DNA in 47% of patients with fulminant hepatitis and 46% of patients with chronic liver disease of unknown aetiology [1, 2] . Moreover, quantitative polymerase chain reaction (PCR) showed that viral DNA is present in infected individuals at a higher titre in hepatic tissue than in serum [2] . Altogether, these data suggested the liver tropism of TTV and its possible capacity to induce liver damage. However, subsequent studies demonstrated a high prevalence of TTV in healthy blood donors and its frequent transmission through transfusion of blood products not associated with illness development [3, 4] . Consequently, several doubts arose about the possible correlation between TTV infection and liver disease. Moreover, although TTV appears to be extensively diffused in the general population of several geographical regions [5] [6] [7] [8] [9] [10] , its prevalence in many areas including the south of Italy is still unknown.
From the virological point of view, TTV has a wide range of sequence divergence, by which it is classified into at least 16 genotypes separated by an evolutionary distance of > 0.30 [11, 12] . The different regions of viral DNA vary from each other in terms of genomic divergence, and the choice of oligonucleotide primers deeply influences the detection of TTV-DNA by PCR techniques [8, 11] . Finally, longitudinal studies showed that TTV frequently persists in the plasma of infected subjects for years [13, 14] . However, the body sites and specific cells from where the virus is shed into the circulation remain poorly defined.
The aims of our study were: (1) to define the tissue tropism of TTV through the analysis of a large series of liver and nonliver tissue samples; (2) to gain information about the prevalence of TTV in patients with hepatic or extrahepatic diseases coming from the south of Italy where viral hepatitis infections show intermediate endemicity; (3) to analyse the presence of TTV in paired serum and cerebrospinal fluids (CSF) to obtain information about the capacity of the virus to invade the central nervous system (CNS); (4) to evaluate possible differences in genotype distribution among different tissues of individual subjects.
MATERIALS AND METHODS

Patients
A total number of 150 patients were included in the study.
We primarily analysed DNA extracts from both serum and liver samples of 128 adult patients (males/females ¼ 89/39, mean age 47.4 years, range 22-70) with chronic liver disease followed-up at the Liver Unit of the Department of Internal Medicine of the Messina University (Table 1) . Ninety-seven (75.8%) of them were randomly selected among individuals with hepatitis C virus (HCV) (64 cases) or hepatitis B virus (HBV) (33 cases) chronic infection, while 31 (24.2%) patients were randomly chosen among cases negative for both HBV and HCV infections. The cause of liver disease in these 31 patients was primary biliary cirrhosis in one case, drugs in three cases, alcohol abuse in five cases, and unknown in 22 cases. All 128 subjects had undergone percutaneous needle liver biopsy. Part of each specimen was processed for histological examination; the rest was immediately frozen and stored at )80°C for subsequent molecular analyses. Serum samples were collected from each patient and frozen until assayed.
We also tested for TTV-DNA 16 subjects with extrahepatic disease (seven males, nine females, mean age 43 years, range 12-71) who consecutively underwent surgical operations (Table 2) . Paired sera and tissue specimens (seven gall bladders, three appendixes, one colon, two omentum, one breast, one thyroid) were obtained from 15 of these patients, whereas serum samples and nontumoral colon and liver tissues were available from one case with colon cancer. In HCV-positive* (n ¼ 64) *All patients were HCV RNA positive. All patients were HBsAg positive. àAll patients were anti-HCV and HBsAg negative. §Chronic hepatitis. addition, we examined paired sera and CSF from six patients who had undergone rachicentesis at the ÔNeurosurgery ClinicÕ (Table 2 ). Brain tissue was also available from one of these six subjects. All patients with extrahepatic disease had normal liver function tests and displayed no evidence of known hepatotropic infections. Finally, we examined peripheral blood mononuclear cells (PBMCs) from five subjects with hepatic (two cases) or extrahepatic (three cases) diseases who were found positive for TTV both in serum and tissue samples. All specimens were stored at )80°C before testing for TTV-DNA.
No patient was infected with the human immunodeficiency virus. All subjects were from Sicily or Calabria, two adjacent regions of southern Italy.
The study protocol was performed according to the principles of the Declaration of Helsinki, and informed consent was obtained from all patients.
DNA extraction
DNA was extracted from frozen tissue specimens as previously described [15] and dissolved in 200 lL of Tris-HCl/ EDTA buffer. Total DNA was extracted from serum samples, PBMCs (obtained by Ficoll Hypaque density gradient centrifugation) and spinal fluids by the use of the QIAamp DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's instructions. Each DNA sample was resuspended in 200 lL of the elution buffer.
Detection of TTV-DNA
We applied the one-stage and/or two-stage PCR assays described by Okamoto et al. [11] to detect TTV in tissue, serum, spinal fluid and PBMC samples. Because the TTV genome is highly variable, its presence was investigated using four sets of previously published primers [11, 16] deduced from coding and noncoding regions of the prototype TTV isolate (TA278) of genotype 1a (Table 3 ). In particular, set primer 1 amplifies a portion of the 5¢-untranslated region (UTR) while set primers 2, 3 and 4 amplify different portions of the open reading frame-1 (ORF-1). As templates, we used one microgram of tissue-or PBMC-derived genomic DNA or onetwentieth of the DNA extracted from 200 lL of serum or spinal fluid. PCR reaction was carried out in a volume of 50 lL containing 10 mM Tris-HCl, 50 mm KCl, 1.5 mm MgCl 2 , 0.2 mm of dNTP mixture, 1 lm each of the external sense and antisense oligonucleotide primers and 1.25 units of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA). When two-stage PCR (nested or heminested) was performed, the second round of amplification was performed under the same conditions except that the template was 5 lL of the first PCR product, and that sense and antisense inner primers were used. The programme of PCR consisted of 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 45 s and extension at 72°C for 45 s, followed by the final extension at 72°C for 7 min. Ten micro litres of each PCR product were electrophoresed on 2% agarose gels and stained by ethidium bromide. Each experiment was repeated at least twice obtaining reproducible results.
Molecular cloning and nucleotide sequencing
A discrete number of randomly selected PCR products from different TTV genomic regions were directly sequenced to confirm the specificity of the amplification reactions following standardized procedures. -CTG GCA TTT TAC CAT TTC CAA AGT T-3¢  2185-2161  NG061  5¢-GGC AAC ATG YTR TGG ATA GAC TGG-3¢  1915-1938  NG063  5¢-CTG GCA TTT TAC CAT TTC CAA AGT T-3¢ 2185-2161 Set 4 [16] TTV B1 5¢-AAC ATA CAC ATG AAT GCC AG-3¢ 2059-2078  TTV B2  5¢-AGT TGT ATT TCG GGT CAA CG-3¢  2459-2440  TTV B3  5¢-GGA AAT GGT AAA ATG CCA GG-3¢  2168-2187  TTV B4 5¢-TAA CAA CCT GTT GGC GAA CG-3¢ 2381-2362
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The N22 region (N22) of ORF-1 is commonly utilized for TTV genotyping. Consequently, several products of amplification obtained by using primer set 3 (see Table 3 ) and corresponding to N22 were analysed to evaluate TTV genomic heterogeneity. In particular, N22-PCR products from sera, tissue specimens (2 livers, appendix, omentum, thyroid) and PBMCs of five patients as well as from serum, liver and colon specimens of one more case were analysed by cloning and sequencing; in analogy, TTV N22-region from both serum and CSF of one patient and from CSF of another one who tested TTV negative in serum were cloned and sequenced. In brief, N22-PCR products were gel-purified using a QIAquick gel extraction kit (Qiagen GmbH, Hilden, Germany), and cloned into the pCR2.1-TOPO vector (TOPO TA cloning kit; Invitrogen, San Diego, CA, USA). Sequencing reactions were performed using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) according to the manufacturer's instructions. The sequencing products were resolved in an automatic DNA sequencer (ABI PRISM 310 Genetic Analyzer; Applied Biosystems); the nested-PCR inner oligonucleotides were used both as forward and reverse sequencing primers. The obtained sequences were compared with 30 published TTV sequences (GenBank accession numbers: AB017610, AF079173, AF122913, AF122914, AF122916, AF122921, AF122919, AB017767, AF247138, AB008394, AB017769, AB017770, AB017771, AB017772, AB017773, AB017768, AB017774, AB017775, AB017776, AB017777, AB017778, AB017779, AB017781, AB017783, AB017613, AB021081, AB021089, AB021082, AB021085, AB021084).
RNA extraction and reverse transcription
Total RNA was extracted from 200 mg of each tissue specimen by a guanidinium isothiocyanate/phenol method (RNAZOL, Invitrogen Life Technologies, Groningen, the Netherlands) and then subjected to digestion with RNase-free DNase I (Promega GmbH, Mannheim, Germany). The obtained RNA was reverse transcribed with SuperScript II RNase H ) reverse transcriptase (Invitrogen Life Technologies) and then subjected to nested PCR by using N22 primers as described above.
Computer analysis of TTV sequences
TTV-DNA sequences were aligned using Clustal W [17] . Evolutionary distances between nucleotide sequences were determined by using the DNADIST Phylip Version 3.5 C (Felsenstein, University of Washington) program. Phylogenetic relationships between sequences were estimated by the neighbour-joining method [18] . The reliability of the phylogenetic results was assessed using 1000 bootstrap replicates [19] . The trees were viewed using the TREEVIEW program [20] . 
Statistical analysis
RESULTS
Detection of TTV-DNA
PCR analysis performed with primer set 1 deduced from the UTR of viral genome allowed detection of TTV-DNA in all the 128 liver specimens from patients with chronic liver disease and all 16 nonliver tissues from cases with extrahepatic pathology (Table 4) . On the contrary, when the same set of PCR primers was used to study the sera from the above-mentioned patients, the rate of TTV-DNA detection was significantly lower as it was found in 77 of 128 (60.1%, P > 0.001) patients with chronic liver disease and in 8 of 16 (50%, P > 0.01) subjects with other pathologies (Table 4) . It should be noted that the rate of detection of serum TTV-DNA was similar among patients with liver disease of different aetiology and cases suffering from different pathologies.
By N22-primers, TTV-DNA was found in 66 (51.5%) liver tissues and in 38 (29.6%) serum samples of patients with liver disease, as well as in six (37.5%) nonhepatic specimens and in six (37.5%) sera of subjects with extrahepatic diseases (table 4) . In particular, by this set of primers TTV-DNA was detected in serum, colon and liver samples from a patient affected with colon cancer. Moreover, all cases positive in the serum were also positive in the corresponding tissue. The other two sets of primers that we used appeared to have a low sensitivity; in fact, set 2 could reveal virus DNA in 17.1% of liver and 12.5% of nonliver specimens, while set 4 detected TTV in 21 and 12.5% of liver and other tissues, respectively. PCR amplifications using both these last sets of primers were unable to detect TTV sequences in any serum sample. It must be underlined that every set of primers used reveals TTV genomes more frequently in tissue specimens than in serum samples. To investigate whether TTV is able to invade the CNS we analysed six paired sera and CSFs obtained from patients who had undergone neurosurgery. As shown in Table 5 , TTV-DNA was detected in four (66.6%) spinal fluids and in serum samples of only two (33.3%) of these four patients either using N22 primer or UTR primer sets. Interestingly, we also succeeded in detecting TTV-DNA through both these primer sets in the brain tissue from one of the subjects showing TTV in the CSF but not in the serum.
By both UTR-and N22-PCR, we also detected TTV-DNA in PBMCs from five patients randomly selected among those previously tested positive for TTV-DNA in both serum and tissue samples.
TTV-DNA cloning and sequencing analyses
To investigate the intra-and inter-individual TTV genomic heterogeneity the N22-PCR fragments from serum, tissue and PBMC samples of five patients as well as from serum, liver and colon specimens of another case were cloned, and four to ten randomly chosen clones from each experiment were used to determine TTV nucleotide sequence. Moreover, the N22 region sequence was also determined in five clones each from serum and CSF of one patient and from the CSF of another one who tested TTV negative in the serum. Thus, we studied by cloning and sequencing procedures TTV isolates from a total number of eight patients (two with hepatic and six with extrahepatic pathologies).
The alignment of the obtained 120 nucleotide sequences revealed a significant degree of heterogeneity among the TTV isolates and no two sequences were identical when derived from different individuals. In addition, a considerable genetic diversity was also noted among TTV sequences derived from single persons. In fact, as many as 106 TTV sequences were different from each other and the evolutionary distances between them were up to 0.72 by Kimura's two-parameter method [21] . Moreover, the different TTV sequences deriving from single individuals could be genetically very close or very distant (evolutionary distances from 0.004 to 0.67).
Overall, the 120 DNA sequences from our TTV isolates along with 30 reference sequences retrieved from GenBank were subjected to a phylogenetic analysis [18, 19] . All sequences were segregated into two major groups corresponding to TTV genotypes 1 and 2, and in Fig. 1 is shown a phylogenetic tree constructed on 120 TTV isolates and on the 6 TTV sequences of genotype 1 and 2 prototypes.
Genotype 1 sequences were segregated into two subtypes (1a and 1b), while genotype 2 group was subdivided into four branches, namely subtypes 2, 2a, 2b and 2c. In particular, 16 of the 120 TTV sequences (13.3%) belonged to genotype 1 (12 to genotype 1a and four to 1b) and 104 sequences (86.6%) belonged to genotype 2 (67 to genotype 2, one to 2a, six to 2b and 30 to 2c) ( Table 6 ). Genotypes and subtypes of TTV were determined by a sequence divergence of 30 and 14%, respectively [2] . There was no significant difference in the prevalence of TTV genotypes or subtypes between patients with liver disease and patients with other pathologies. Moreover, the patient whose serum, liver and colon specimens were analysed showed a prevalence of sequences of genotype 2 in liver and serum samples and of genotype 1 in colon tissue. In analogy, the analysis of ten clones derived from the paired serum and CSF of one patient revealed the presence of distinct genotypes in the two biological liquids: genotype 1a in the CSF and genotype 2c in the serum (Table 6 ). Thus, the eight studied patients were each infected with different TTV variants, belonging to various genotypes or subtypes, and showed prevalent strains distinct among the different body districts analysed. Several of the cloned N22 region sequences contained premature stop codons in phase with ORF-1. Interestingly, these peculiar TTV strains represented the dominant population in serum specimens of two patients, one of whom had chronic liver disease and the other extrahepatic pathology.
The GenBank accession numbers of the TTV sequences obtained in this study are AY137849-AY137960.
Detection of TTV mRNA in tissues
Nested RT-PCR was performed to verify the presence of TTV mRNA in six various type of tissues analysed in this study TTV-DNA in serum and tissue specimens 99 (breast, colon, omentum, gallbladder, liver and thyroid). By using N22 primers for nested PCR, TTV mRNAs could be detected in all tissues tested (data not shown).
DISCUSSION
In this study we evaluated the prevalence of TTV infection in subjects with different hepatic and extrahepatic pathologies.
To this purpose we tested a large series of paired serum and tissue samples from individual patients through PCR assays performed with four different sets of primers deduced from both 5¢-UTR and ORF-1. By using TTV-UTR primers, we found that viral DNA was present in 100% of the liver tissues analysed as well as in 100% of nonhepatic tissue specimens, clearly showing that TTV does not possess a preferential tropism for liver cells but is ubiquitously distributed in the body tissues. Moreover, these data show that TTV is extremely diffuse in our geographical area and suggest that different routes of transmission, besides the parenteral one, must contribute to such an extensive virus spread. This hypothesis is in agreement with the observation that TTV may be excreted in faeces via secretion from the liver into the bile [22, 23] , thus suggesting a possible faecaloral route of virus transmission. The N22 primers proved to be much less sensitive than UTR primers in detecting TTV-DNA both in sera and in tissue samples of the different groups of patients examined. The sensitivity of the other two sets of primers deduced from ORF-1 and additionally used in this study was even lower than that of N22 primers. Hence, as previously suggested [24, 25] , the use of primers from 5¢-UTR TTV region should be recommended for studies on TTV prevalence. The presence of TTV in the totality of tissues analysed compared with the significantly lower prevalence in the correspondent sera demonstrate that the detection of TTV-DNA in tissue Fig. 1 Phylogenetic analysis of TTV isolates. A phylogenetic tree was constructed on a sequence of 222 bp from 120 isolates and the prototype TTV of genotypes 1 and 2. TTV isolates from the four cases with extrahepatic pathology (14, 15, 16 and st) are indicated as 14S, 15S, 16S and stS when obtained from serum samples and as 14T, 15T, 16T, stF and stC when obtained from tissue samples (omentum, appendix, thyroid gland, liver and colon, respectively). For cases 14-16 viral isolates from PBMCs are named 14L, 15L and 16L, respectively. TTV isolates from the two patients with liver disease (C and R) are indicated as CS and RS when obtained from serum samples, CL and RL when obtained from PBMCs and CT and RT when obtained from tissue specimens (liver). FL, FS and GL represent TTV isolates from spinal fluid and serum of patient F and spinal fluids of case G respectively. A number (from 1 to 10) has been added to each TTV isolate in order to distinguish the different clones analysed. b specimens is not the consequence of a contamination with circulating serum TTV, as was previously supposed [16] . In addition, the marked discrepancy in the prevalence of TTV between tissue samples and sera might suggest that viral genomes may persist in infected cells after they are cleared from the serum, or that the levels of TTV replication are so low that the circulating virions can be undetectable in spite of the very sensitive PCR techniques used.
An interesting finding of our study was the detection of premature stop codons in TTV clones derived from the same patients and demonstrating the production of a proportion of defective TTV genomes in the context of the infecting viral populations. The occurrence of mutations preventing the expression of the full-length ORF1-encoded protein was previously described in one case [26] . Now we report that the presence of such premature stop codons is a quite frequent event and, theoretically, it might be a mechanism responsible for the low TTV viraemia levels usually observed in infected individuals.
Phylogenetic analysis of TTV isolates revealed the exclusive presence of genotypes 1 and 2 in the various biological samples obtained from the examined patients. However, the fact that the N22 primer set commonly used for genotyping is much less sensitive than the UTR primer set in detecting TTV-DNA implies that a large number of TTV isolates remain unclassified. In our study N22 primers were unable to detect about half of the UTR-PCR positive TTV isolates both in tissue and serum samples, and it is conceivable that N22-PCR negative/UTR-PCR positive TTV strains might belong to genotypes different from 1 and 2. In summary and according to previous reports [27] [28] [29] , our data show the coexistence of multiple genotypes and genetic variants in each infected person. The wide spectrum of intra-individual genomic heterogeneity of TTV may be a valid explanation for the capability of TTV to replicate in various tissue types, as evidenced in this study through the detection of viral mRNA and in accordance with other very recent reports [27, 30] . In this context, it is of interest that liver and colon of one of our patients appeared to be infected with different TTV genotypes. These results, together with the ability of TTV to persist in different cell types, indicate that co-infection and/or super-infection by divergent viral strains are frequent occurrences. Moreover, the wide distribution of each genotype and subtype in different body tissues do not allow to attribute them any peculiar tropism.
Finally, the screening of paired serum and CSF samples from six patients who had undergone neurosurgery showed that four individuals had TTV in the CSF but only two of them had detectable viral genomes also in the serum. Interestingly, TTV-DNA was detected in the brain tissue of one subject positive in CSF but not in the serum. In addition, sequence comparison of TTV-DNA clones from the serum and CSF of one of the cases revealed that the TTV genotypes of the two body fluids were different; indeed, only TTV sequences of genotype 2c were found in the serum and only TTV sequences of genotype 1a could be detected in the spinal fluid. Similar results were reported in a very recent publication [30] . Taken together, these data suggest that TTV is capable of invading the CNS.
In conclusion, our study shows that TTV is diffused in all the general population of our area and appears to be able to infect many (all?) human body tissues. It is unknown whether this virus may have any pathogenic property, and our data clearly indicate that the hypothesis of a possible correlation between TTV infection and liver disease is at present unjustified.
